BRPI0922022A2 - Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos - Google Patents
Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usosInfo
- Publication number
- BRPI0922022A2 BRPI0922022A2 BRPI0922022A BRPI0922022A BRPI0922022A2 BR PI0922022 A2 BRPI0922022 A2 BR PI0922022A2 BR PI0922022 A BRPI0922022 A BR PI0922022A BR PI0922022 A BRPI0922022 A BR PI0922022A BR PI0922022 A2 BRPI0922022 A2 BR PI0922022A2
- Authority
- BR
- Brazil
- Prior art keywords
- kits
- prevention
- individual
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/137—Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
Abstract
COMPOSIÇÕES FARMACÊUTICAS, KITS, MÉTODOS DE PREVENÇÃO OU TRATAMENTO DE DOENÇAS NEURAIS DO INDIVÍDUO E RESPECTIVOS USOS. São proporcionados uma composição farmacêutica para prevenção e tratamento de uma doença neural incluindo pelo menos um selecionado a partir do grupo que consiste em células-tronco mesenquimais (MSCs), uma solução de cultura das MSCs, activina A, PF4, decorina, galectina 3, GDF15, glipican 3, MFRP, ICAMS, IGEBPY7, PDGF-AA, SPARCL1, trombospondina-1, WISP1, progranulina, IL-4, um fator induzindo a expressão do mesmo e qualquer combinação dos mesmos e um método para isso.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19329308P | 2008-11-14 | 2008-11-14 | |
KR20080113465 | 2008-11-14 | ||
KR1020090072114A KR20100054711A (ko) | 2008-11-14 | 2009-08-05 | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
PCT/KR2009/006712 WO2010056075A2 (en) | 2008-11-14 | 2009-11-16 | Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0922022A2 true BRPI0922022A2 (pt) | 2017-07-11 |
Family
ID=42279397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0922022A BRPI0922022A2 (pt) | 2008-11-14 | 2009-11-16 | Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos |
Country Status (11)
Country | Link |
---|---|
US (1) | US10238692B2 (pt) |
EP (1) | EP2365816B1 (pt) |
JP (2) | JP5650122B2 (pt) |
KR (4) | KR20100054711A (pt) |
CN (2) | CN102281883A (pt) |
AU (1) | AU2009314797B2 (pt) |
BR (1) | BRPI0922022A2 (pt) |
CA (1) | CA2743620C (pt) |
MX (1) | MX2011005118A (pt) |
MY (1) | MY179052A (pt) |
WO (1) | WO2010056075A2 (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9387226B2 (en) | 2006-11-30 | 2016-07-12 | Medipost Co., Ltd | Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells |
US9358320B2 (en) | 2008-04-25 | 2016-06-07 | Allosource | Multi-layer tissue patches |
US9480549B2 (en) | 2008-04-25 | 2016-11-01 | Allosource | Multi-layer tissue patches |
KR20100054711A (ko) | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
US20140286911A1 (en) | 2013-03-15 | 2014-09-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
WO2011106476A1 (en) * | 2010-02-25 | 2011-09-01 | Abt Holding Company | Modulation of microglia activation |
WO2012060517A1 (ko) * | 2010-11-05 | 2012-05-10 | 하이스템(주) | Cd45가 발현되는 중간엽 줄기세포를 유효성분으로 포함하는 신경질환 예방 및 치료용 의약 조성 |
CN103491974A (zh) * | 2010-11-16 | 2014-01-01 | 神经机能生命科学公司 | 用于提高中性溶酶的表达与活性的方法 |
JP5784754B2 (ja) * | 2011-02-02 | 2015-09-24 | メディポスト・カンパニー・リミテッドMedipost Co., Ltd. | 神経疾患の予防または処置のためのicam−1の使用 |
WO2012164137A1 (es) | 2011-05-30 | 2012-12-06 | Fundación Investigación En Regeneración Del Sistema Nervioso | Células madre y células de la estirpe neural derivadas de la glía envolvente olfatoria, y sus aplicaciones |
EP2723364A1 (en) | 2011-06-24 | 2014-04-30 | National University of Ireland Galway | Cell secreted proteins for the treatment of myocardial infarction |
WO2013039000A1 (ja) * | 2011-09-13 | 2013-03-21 | Ochiya Takahiro | アルツハイマー病の予防または治療のための医薬品 |
CN103087983A (zh) * | 2011-10-27 | 2013-05-08 | 北京清美联创干细胞科技有限公司 | 一种药物诱导肌肉间充质干细胞增殖和分化的方法及应用 |
US9162011B2 (en) | 2011-12-19 | 2015-10-20 | Allosource | Flowable matrix compositions and methods |
KR20130104924A (ko) * | 2012-03-16 | 2013-09-25 | (주)히스토스템 | 항바이러스 작용을 갖는 제대혈 다분화능 줄기세포 유래의 세포활성화 물질을 포함하는 조성물 및 이의 제조방법 |
EP2659897A1 (en) * | 2012-05-02 | 2013-11-06 | Philipps-Universität Marburg | Stem cell derived composition for the treatment of acute injury and degenerative diseases |
US10493104B2 (en) | 2013-02-20 | 2019-12-03 | Samsung Life Public Welfare Foundation | Composition for treating inflammatory brain diseases which includes stem cell as active ingredient |
AU2014248873B2 (en) | 2013-03-13 | 2017-03-23 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
WO2014141219A1 (en) * | 2013-03-15 | 2014-09-18 | Blue Horizon International Llc | Umbilical cord blood derived stem cell transplantation for the treatment of neural disorder |
US20140286910A1 (en) * | 2013-03-19 | 2014-09-25 | Nikolai Tankovich | Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity |
KR101455933B1 (ko) * | 2013-05-28 | 2014-10-31 | 가톨릭대학교 산학협력단 | 인간골수유래 중간엽줄기세포와 미노사이클린 병용투여를 통한 다발성경화증 치료제 및 치료방법 |
CN103599129A (zh) * | 2013-11-07 | 2014-02-26 | 唐明淇 | 一种人干细胞组合物在制备用于治疗阿尔茨海默症的药物中的用途 |
AU2014360195B2 (en) | 2013-12-06 | 2018-02-08 | Allosource | Method of drying sheets of tissue |
US20160143950A1 (en) * | 2013-12-22 | 2016-05-26 | Nikolai Tankovich | Stem cells and stem cell factors for inhibiting the progression of alzheimer's disease |
CN103751228B (zh) * | 2014-01-27 | 2016-04-20 | 贵州神奇药物研究院 | 治疗老年痴呆的药物及其制备方法 |
CN104758923A (zh) * | 2015-03-11 | 2015-07-08 | 黑龙江天晴干细胞股份有限公司 | 一种治疗神经损伤的干细胞制剂及其制备方法 |
EP3342858B1 (en) | 2015-08-28 | 2023-10-04 | Rohto Pharmaceutical Co., Ltd. | Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells |
EP3450548A4 (en) * | 2016-04-27 | 2019-11-20 | Rohto Pharmaceutical Co., Ltd. | MESENCHYMAL STEM CELL EXPRESSING AT LEAST ONE CELLULAR SURFACE MARKER SELECTED IN THE GROUP COMPRISED OF CD201, CD46, CD56, CD147 AND CD165 AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION CONTAINING THE MESENCHYMAL STEM CELL, AND PROCESS FOR PREPARING THE SAME |
AU2017258058B2 (en) * | 2016-04-28 | 2023-04-13 | Nipro Corporation | Synapse formation agent |
IL264825B (en) * | 2016-08-14 | 2022-08-01 | Univ Ramot | Exosomes from mesenchymal cells for the treatment of neurological diseases |
US10772986B2 (en) | 2017-01-26 | 2020-09-15 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
US20200108099A1 (en) | 2017-02-15 | 2020-04-09 | Rohto Pharmaceutical Co., Ltd. | Therapeutic agent for pulmonary fibrosis, ptprr expression-promotor, and kit for treatment of pulmonary fibrosis |
EP3591038A4 (en) | 2017-03-03 | 2020-11-25 | Rohto Pharmaceutical Co., Ltd. | MESENCHYMATIC STEM CELL, AND PHARMACEUTICAL COMPOSITION |
EP3591037A4 (en) | 2017-03-03 | 2020-11-11 | Rohto Pharmaceutical Co., Ltd. | MESENCHYMATIC STEM CELL AND THERAPEUTIC AGENT AGAINST LIVER DISEASES |
EP3593809A4 (en) | 2017-03-08 | 2021-01-06 | Rohto Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING MMR1 POSITIVE MESENCHYMATIC STEM CELLS IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF A FIBROSIS-ASSOCIATED DISEASE, ITS PREPARATION PROCESS, AND PROCESS FOR THE PROPHYLACTIC TREATMENT OF FIBROSIS-ASSOCIATED DISEASE OR A FIBROSIS-ASSOCIATED THERAPEUTIC TREATMENT, AND PROCESS FOR THE PROPHYLACTIC TREATMENT OF FIBROSIS ASSOCIATED OR THERAPEUTIC TREATMENT MMR-POSITIVE MESENCHYMATIC STEM CELLS |
EP3636271A4 (en) | 2017-06-09 | 2021-03-03 | Osaka University | THERAPEUTIC FOR DILATED CARDIOMYOPATHY |
CN107320495A (zh) * | 2017-06-19 | 2017-11-07 | 北正赛欧(北京)生物科技有限公司 | 用于促进细胞损伤修复的组合物及其应用 |
EP3738598A4 (en) | 2018-01-12 | 2021-06-09 | Osaka University | AGENT PROMOTING NORMAL DIFFERENTIATION AND MATURATION OF LAMINATED EPITHELIAL SQUAMEUS CELLS, THERAPEUTIC AGENT FOR EPITHELIAL DISEASE, AND PROCESS TO PROMOTE NORMAL DIFFERENTIATION AND MATURATION OF SQUAMEOUS SQUAMEOUS CELLS |
KR102053868B1 (ko) | 2018-01-31 | 2020-01-22 | 가톨릭대학교 산학협력단 | 하비갑개 유래 중간엽 줄기세포를 유효성분으로 포함하는 퇴행성 신경계질환 예방 또는 치료용 약학적 조성물 |
GB201803010D0 (en) * | 2018-02-26 | 2018-04-11 | Royal Holloway & Bedford New College | Neurodegenerative disorders |
WO2019203555A1 (ko) * | 2018-04-17 | 2019-10-24 | 한국생명공학연구원 | Progranulin 단백질을 포함하는 간질환의 예방 또는 치료용 조성물 |
KR20190143833A (ko) | 2018-06-21 | 2019-12-31 | 재단법인 아산사회복지재단 | 신경퇴행성 질환 예방 또는 치료용 조성물 |
CN109182260A (zh) * | 2018-09-11 | 2019-01-11 | 邵勇 | 一种体外培养胎膜间充质干细胞的方法 |
WO2020181411A1 (zh) * | 2019-03-08 | 2020-09-17 | 玛旺干细胞医学生物科技股份有限公司 | 间充质干细胞在预防或治疗情绪疾病上的医药用途 |
CN111635886A (zh) * | 2020-07-02 | 2020-09-08 | 成都恩喜医疗管理有限公司 | 一种间充质干细胞的制备方法与应用 |
CA3194052A1 (en) * | 2020-09-08 | 2022-03-17 | Longeveron, Inc. | Treatment of alzheimer's disease with allogeneic mesenchymal stem cells |
JP2023550542A (ja) * | 2020-10-26 | 2023-12-01 | ハダシット メディカル リサーチ サービシズ アンド ディベロップメント リミテッド | 間葉系幹細胞およびそれらの培養 |
WO2022176735A1 (ja) | 2021-02-22 | 2022-08-25 | ロート製薬株式会社 | 糖尿病の予防及び/又は治療剤 |
WO2023054918A1 (ko) * | 2021-09-30 | 2023-04-06 | 주식회사 디자인셀 | 네프릴라이신을 과발현하는 줄기세포, 이의 배양액 및 이들로부터 분리된 엑소좀을 유효성분으로 포함하는 인지기능장애의 예방 또는 치료용 약학적 조성물 |
WO2023080413A1 (ko) | 2021-11-02 | 2023-05-11 | 주식회사 디자인셀 | 줄기세포 배양액 및 이로부터 분리된 엑소좀을 유효성분으로 포함하는 안구 질환의 예방 또는 치료용 약학적 조성물 |
WO2023140348A1 (ja) | 2022-01-24 | 2023-07-27 | 国立大学法人広島大学 | 精子処理用組成物、精子運動性改善剤、精子受精能保持剤、精子運動性改善方法及び精子受精能保持方法 |
WO2023140347A1 (ja) | 2022-01-24 | 2023-07-27 | 国立大学法人広島大学 | 精子処理用組成物、精子運動性改善剤、精子受精能保持剤、精子運動性改善方法及び精子受精能保持方法 |
WO2023154953A1 (en) * | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
CN115192609A (zh) * | 2022-05-10 | 2022-10-18 | 湖南中南大学湘雅口腔医院 | 间充质干细胞在制备治疗抑郁症的药物中的应用 |
CN116115738B (zh) * | 2023-02-22 | 2024-09-03 | 重庆大学 | 细胞因子Igfbp7在制备治疗小鼠老年性肌肉萎缩的药物中的应用 |
CN117547597A (zh) * | 2023-11-28 | 2024-02-13 | 四川大学华西医院 | 基因Wisp1在制备调控MSCs抗衰老表型药物中的应用 |
CN117384857B (zh) * | 2023-12-08 | 2024-03-19 | 上海兴瑞一达生物科技有限公司 | 一种pf4基因修饰的间充质干细胞外泌体及其应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8013A (en) * | 1851-04-01 | Improvement in wheat-fans | ||
US7354588B1 (en) | 1987-05-04 | 2008-04-08 | Dana Farber Cancer Institute | Functional derivatives of ICAM-1 with altered ability to bind LFA-1 or HRV |
US5733542A (en) * | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
US20030060398A1 (en) * | 1997-09-19 | 2003-03-27 | Gluckman Peter David | Neuronal rescue agent |
US5837576A (en) | 1997-10-31 | 1998-11-17 | Vanguard International Semiconductor Corporation | Method for forming a capacitor using a silicon oxynitride etching stop layer |
US6900299B1 (en) | 1999-03-11 | 2005-05-31 | University Of South Florida | Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection |
DE60023673T2 (de) * | 1999-03-12 | 2006-07-20 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford | Dna-impfung zur behandlung von autoimmunerkrankungen |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
PT1179067E (pt) * | 1999-05-17 | 2007-01-31 | Biopharm G Biotechnolo Entwi V | Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta |
US20040208858A1 (en) * | 2000-04-12 | 2004-10-21 | Gihan Tennekoon | Therapeutic uses for mesenchymal stromal cells |
CA2413910A1 (en) | 2000-06-26 | 2002-12-27 | Renomedix Institute Inc. | Cell fractions containing cells capable of differentating into neural cells |
US20040037775A1 (en) | 2000-08-01 | 2004-02-26 | Siahaan Teruna J. | Leukocyte internalized peptide-drug conjugates |
US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
KR100449141B1 (ko) | 2001-04-19 | 2004-09-21 | (주)라이프코드 | 간엽 간세포를 신경세포로 분화시키는 방법 |
ATE365793T1 (de) | 2002-02-19 | 2007-07-15 | Medipost Co Ltd | Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe |
US20090192105A1 (en) | 2002-02-20 | 2009-07-30 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA) |
KR100519227B1 (ko) | 2002-08-17 | 2005-10-07 | 서해영 | 간엽 줄기세포를 신경세포로 분화시키는 방법 |
US20040203142A1 (en) | 2003-04-14 | 2004-10-14 | Reliance Life Sciences Pvt. Ltd. | Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes |
EP1674566B1 (en) | 2003-09-09 | 2011-04-13 | Keio University | Method of promoting subsistence and/or proliferation of neural stem cell and promoting extension of neurite, promoter therefor, pharmaceutical composition containing neural stem cell, method of assay and method of screening |
US20060094064A1 (en) | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
JP4027359B2 (ja) | 2003-12-25 | 2007-12-26 | キヤノン株式会社 | マイクロ揺動体、光偏向器、画像形成装置 |
CA2564679C (en) * | 2004-03-22 | 2015-06-23 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
EP1767617A1 (en) * | 2005-09-26 | 2007-03-28 | Letizia Mazzini | Mesenchymal stem cells isolation and expansion method and uses thereof |
EP1951665A1 (en) | 2005-11-14 | 2008-08-06 | Dominion Pharmakine S.L. | Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof |
US20070253931A1 (en) | 2006-01-12 | 2007-11-01 | Osiris Therapeutics, Inc. | Use of mesenchymal stem cells for treating genetic diseases and disorders |
KR100792184B1 (ko) | 2006-05-12 | 2008-01-07 | 재단법인서울대학교산학협력재단 | 개의 제대혈, 태반 및 개 태아의 심장 유래 다분화능 성체줄기세포, 그 제조방법 및 이를 함유하는 세포 치료제 |
KR20080049562A (ko) * | 2006-11-30 | 2008-06-04 | 가톨릭대학교 산학협력단 | 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는 신경손상 질환 치료제 |
KR20100054711A (ko) | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
-
2009
- 2009-08-05 KR KR1020090072114A patent/KR20100054711A/ko unknown
- 2009-11-11 KR KR1020090108662A patent/KR20100054731A/ko active Search and Examination
- 2009-11-16 MX MX2011005118A patent/MX2011005118A/es active IP Right Grant
- 2009-11-16 US US13/129,363 patent/US10238692B2/en active Active
- 2009-11-16 EP EP09826307.2A patent/EP2365816B1/en active Active
- 2009-11-16 BR BRPI0922022A patent/BRPI0922022A2/pt not_active IP Right Cessation
- 2009-11-16 AU AU2009314797A patent/AU2009314797B2/en active Active
- 2009-11-16 JP JP2011536252A patent/JP5650122B2/ja active Active
- 2009-11-16 WO PCT/KR2009/006712 patent/WO2010056075A2/en active Application Filing
- 2009-11-16 KR KR1020090110502A patent/KR101114800B1/ko active IP Right Grant
- 2009-11-16 CA CA2743620A patent/CA2743620C/en active Active
- 2009-11-16 CN CN2009801544024A patent/CN102281883A/zh active Pending
- 2009-11-16 MY MYPI2011002115A patent/MY179052A/en unknown
- 2009-11-16 CN CN201710098386.8A patent/CN107412263A/zh not_active Withdrawn
-
2011
- 2011-07-19 KR KR1020110071552A patent/KR101533989B1/ko active IP Right Grant
-
2014
- 2014-06-25 JP JP2014129743A patent/JP5893084B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN107412263A (zh) | 2017-12-01 |
JP2014240388A (ja) | 2014-12-25 |
CN102281883A (zh) | 2011-12-14 |
KR101114800B1 (ko) | 2012-03-13 |
KR20100054759A (ko) | 2010-05-25 |
KR20100054711A (ko) | 2010-05-25 |
CA2743620A1 (en) | 2010-05-20 |
EP2365816A4 (en) | 2013-05-15 |
MX2011005118A (es) | 2011-09-26 |
EP2365816A2 (en) | 2011-09-21 |
WO2010056075A2 (en) | 2010-05-20 |
WO2010056075A3 (en) | 2010-09-30 |
MY179052A (en) | 2020-10-26 |
JP5893084B2 (ja) | 2016-03-23 |
US20110262393A1 (en) | 2011-10-27 |
KR101533989B1 (ko) | 2015-07-06 |
JP5650122B2 (ja) | 2015-01-07 |
US10238692B2 (en) | 2019-03-26 |
AU2009314797B2 (en) | 2012-10-11 |
CA2743620C (en) | 2017-08-15 |
JP2012508733A (ja) | 2012-04-12 |
EP2365816B1 (en) | 2017-06-28 |
KR20110087263A (ko) | 2011-08-02 |
KR20100054731A (ko) | 2010-05-25 |
AU2009314797A1 (en) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0922022A2 (pt) | Composições farmacêuticas, kits, métodos de prevenção ou tratamento de doenças neurais do indivíduo e respectivos usos | |
Caliari et al. | Structural and biochemical modification of a collagen scaffold to selectively enhance MSC tenogenic, chondrogenic, and osteogenic differentiation | |
Kim et al. | Hesperetin alleviates the inhibitory effects of high glucose on the osteoblastic differentiation of periodontal ligament stem cells | |
Zhou et al. | The effect of quercetin on the osteogenesic differentiation and angiogenic factor expression of bone marrow-derived mesenchymal stem cells | |
Kang et al. | Cellular and molecular stimulation of adipose‐derived stem cells under hypoxia | |
Shi et al. | Modulation of chondrocyte motility by tetrahedral DNA nanostructures | |
CA2902237C (en) | Compounds, compositions, methods, and kits relating to telomere extension | |
Rezai Rad et al. | Impact of tissue harvesting sites on the cellular behaviors of adipose‐derived stem cells: Implication for bone tissue engineering | |
JP6751465B2 (ja) | クロモン誘導体の上皮間葉移行抑制活性を利用した線維症予防及び治療用医薬組成物としての新規用途 | |
Fatima et al. | Selenium nanoparticles by moderating oxidative stress promote differentiation of mesenchymal stem cells to osteoblasts | |
BRPI0608109A2 (pt) | tratamento de distúrbios ósseos | |
BRPI0809594A2 (pt) | polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s) | |
Xu et al. | LncRNA‐TWIST1 promoted osteogenic differentiation both in PPDLSCs and in HPDLSCs by inhibiting TWIST1 expression | |
NO20092522L (no) | Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA | |
Onizuka et al. | ZBTB16 as a downstream target gene of osterix regulates osteoblastogenesis of human multipotent mesenchymal stromal cells | |
Rbia et al. | Seeding decellularized nerve allografts with adipose-derived mesenchymal stromal cells: An in vitro analysis of the gene expression and growth factors produced | |
Zhai et al. | Cross-talk of MicroRNA and hydrogen sulfide: A novel therapeutic approach for bone diseases | |
Zainal Ariffin et al. | In vitro chondrogenesis transformation study of mouse dental pulp stem cells | |
Alibardi | The regenerating tail blastema of lizards as a model to study organ regeneration and tumor growth regulation in amniotes | |
Santos et al. | Mesenchymal stem cells repress osteoblast differentiation under osteogenic‐inducing conditions | |
Yi et al. | Effects of electromagnetic field frequencies on chondrocytes in 3D cell‐printed composite constructs | |
Wang et al. | IL1β inhibits differentiation of cementoblasts via microRNA‐325‐3p | |
Ido et al. | Expression of chondrogenic potential of mouse trunk neural crest cells by FGF2 treatment | |
Wrona et al. | Derivation and characterization of porcine vocal fold extracellular matrix scaffold | |
Byun et al. | Effects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |